Form 4: Globus Medical CEO Daniel Scavilla Acquires 140,000 Stock Options

Globus Medical's CEO, Daniel T. Scavilla, was granted 140,000 stock options on January 23, 2025, according to a Form 4 filing with the SEC.

Summary

• Daniel T. Scavilla, the President and CEO of Globus Medical Inc. (GMED), has been granted 140,000 stock options.
• The transaction occurred on January 23, 2025.
• The exercise price of the options is $92.42.
• The options vest over a four-year period, with one-fourth vesting on January 1, 2026, and the remainder vesting monthly over the subsequent 36 months.
• The options expire on January 23, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the medical device industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the medical device industry.
• Comparing the size and vesting schedule of this grant to those of CEOs at similarly sized medical device companies (e.g., NuVasive, Stryker, Medtronic) would provide a benchmark for assessing its competitiveness and alignment with industry norms.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CEO to drive long-term value.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates

Keywords

Stock Options, Form 4, Globus Medical, GMED, CEO, Daniel Scavilla, Executive Compensation